


Matt Wipperman
Associate Director, Digital Medicine
Regeneron Pharmaceuticals, Inc.



Dr. Matthew Wipperman works in Digital Medicine at Regeneron Pharmaceuticals, where he focuses on the strategy and application of digital sensor technology-derived digital biomarkers to the Regeneron portfolio. Matthew joined Regeneron in 2019 as a Quantitative Translational Scientist in Early Clinical Development & Experimental Sciences. Across biomarker and clinical research studies, he contributes to strategy, design, and exploratory data analyses across biomarker modalities.

This work drives the discovery and understanding of innovative biomarkers and clinical trial endpoints, the elucidation of mechanisms of action and drug pharmacodynamics, identification of sub-populations where pharmaceutical interventions will be effective, and exploration of alternative indications for approved drugs. He drives digital biomarker strategy for clinical development programs, aiming to transform drug trial outcome measures by quantifying patient function in real-world settings.

Matthew actively initiates and leads collaborations with diverse teams across clinical, research, regulatory, and external functions, to ensure scientific and clinical success of projects. He holds a BA and PhD in Chemistry, and an MSc in Clinical and Translational Science, with 15 years of experience in laboratory, computational, and basic scientific domains. Prior to Regeneron, he worked in clinical biomarker research at Sloan Kettering, where he led clinical biomarker and immunology work in infectious disease clinical research. He also continues to sit on the faculty in the Department of Medicine at Weill Cornell Medicine as a courtesy appointment, reflecting his ongoing connection to academic medicine.